Introduction
Vogt-Koyanagi-Harada (VKH) disease is a T-cell mediated multisystemic
autoimmune inflammatory disorder characterized by skin, ocular, auditory
and neurologic involvement. The T-cell mediated granulomatous
intraocular inflammation is responsible for vitritis, disk edema, serous
retinal detachments, and eventual sunset glow fundus.1T-cells target melanocytes, with an ensuing cascade leading to four
distinct disease phases as follows: prodromal, uveitis, convalescent,
and recurrent.2 VKH symptoms include headache,
meningismus, hearing loss, poliosis, alopecia, and
vitiligo.3 It is most prevalent in Asians, Native
Americans, Hispanics, and Middle Easterners. If promptly and adequately
treated, patients can experience good outcomes and avoid complications
including sunset glow fundus, cataracts, glaucoma, subretinal fibrosis,
and choroidal neovascularization. Some studies have reported the link
between some viral infections such as cytomegalovirus (CMV) and Epstein
Barr virus (EBV) and the development of VKH. It has been postulated that
similarity between peptides on melanocytes and some exogenous viral
peptides lead to adverse T-cells attacks on melanocytes-containing
tissues and lead to the symptoms seen in VKH.4 We
report a case of a VKH syndrome in a patient diagnosed with COVID-19.